FDA approves alirocumab for homozygous FH as addon therapy

The US food and drug administration (FDA) has expanded approval of Praluent (alirocumab) injection for adult patients with homozygous familial hypercholesterolemia (HoFH) as an add on therapy to other treatments for HoFH. Praluent was originally¬†…

Read more

Show More

Related Articles

Back to top button